A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

Part of paid clinical trials in Milwaukee, Wisconsin.

Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Study ID
NCT06794268
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lisocabtagene maraleucel — BIOLOGICAL
    As per product label

Study Details

The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities

Key Dates

First listed
Jan 27, 2025
Start date
Feb 4, 2025
Status verified
Feb 2025
Primary completion
Aug 31, 2044
Completion
Aug 31, 2044

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Participants receiving lisocabtagene maraleucel treatment

Primary Outcome Measure

Incidence of adverse events (AEs) of interest [ Time Frame: Up to 15 years ]

Central Contacts

  • BMS Study Connect Contact Center www.BMSStudyConnect.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (1)

FacilityCityStateZIPSite coordinators
CIBMTRMilwaukeeWisconsin53226-

Find similar trials in Milwaukee, WI

By research site
CIBMTR· Milwaukee, WI

Related Studies